HAP Trading’s Celldex Therapeutics CLDX Stock Holding History

HAP Trading’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-6,667	Closed	-$13K	–	1123
2016 Q2	$13K	Sell	6,667 -3,746	-36%	-$238K	﹤0.01%	769
2016 Q1	$82K	Buy	+10,413	New	+$1.17M	0.01%	480

Other funds holding CLDX

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HAP Trading's CLDX Position: Q1 2016 in Review

HAP Trading sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 3,436 shares — an estimated $387K sold.

HAP Trading first reported a position in CLDX in Q1 2015 and held it in 4 quarters. The position peaked at $2.6M in Q1 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

HAP Trading reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
HAP Trading sold 3,436 Celldex Therapeutics shares in Q1 2016, an estimated $387K.
HAP Trading first reported a position in Celldex Therapeutics in Q1 2015 and held it in 4 quarters.
HAP Trading's Celldex Therapeutics position peaked at $2.6M in Q1 2015.
145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on HAP Trading's 13F filing for Q1 2016, filed 12 May 2016.